Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3421-3440 of 3,900 trials

Lung Cancer Treatment: Divarasib and Pembrolizumab

We are studying a new treatment combination for patients with advanced non-small cell lung cancer that has a specific genetic mutation. The goal is to see if this new approach improves survival and quality of life compared to standard treatments.

Advanced Non-Squamous Non-Small Cell Lung Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Wiskott-Aldrich Syndrome: Long-term Study of Gene Therapy

We are examining the long-term safety and effectiveness of a gene therapy treatment for individuals with Wiskott-Aldrich Syndrome. This study aims to provide insights into how well the treatment works over time.

Wiskott-Aldrich Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteHematologyInfectious Diseases

Siponimod for Progressive Multiple Sclerosis

We are studying how siponimod affects brain lesions and nerve damage in patients with secondary progressive MS. The trial also looks at its impact on cognitive health and long-term safety.

Progressive Multiple Sclerosis>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesNeurology

Leber Congenital Amaurosis: Sepofarsen Treatment Study

We are investigating a new treatment for people with Leber Congenital Amaurosis caused by a specific genetic mutation. The study will assess how well it improves vision and its safety over time.

Leber's Congenital Amaurosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesOphthalmology

Idiopathic Membranous Nephropathy: AP1189 Study

We are exploring whether the medication AP1189 can improve kidney function and reduce protein in urine for patients with idiopathic membranous nephropathy. This study involves patients already receiving ACE inhibitors or angiotensin II receptor blockers.

Membranous Nephropathy1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementInternal MedicineNephrology

Neuroinflammation in Major Depressive Disorder: InflaDep Study

We are investigating the patterns of neuroinflammation in people with major depressive disorder compared to those in remission and healthy individuals. This study may help us understand the links between inflammation and depression symptoms.

Depressive Disorder>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesPsychiatry

Ketamine for Treating Disorders of Consciousness After Coma

We are studying whether intravenous ketamine can help patients regain consciousness after a coma. The trial also aims to identify which patients may respond best to this treatment.

Severe Brain Injury and Disorder of Consciousness>2 yearsEfficacy phase (II)Standard MedicinesPartially RemoteNeurologyPsychiatry

Ulcerative Colitis: Tofacitinib's Impact on Blood Clotting

We are studying how tofacitinib affects blood clotting and platelet function in patients with ulcerative colitis. This trial also compares its effects to other treatments and collects samples for future research.

Ulcerative Colitis3-6 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyHematology

STOP-LEUKEMIA: Metformin for Blood Disorders

We are investigating whether metformin can help prevent leukemia in patients with clonal cytopenia of undetermined significance and lower-risk myelodysplastic syndromes. This study will assess the safety of metformin and explore how it may affect disease progression.

Myelodysplastic Syndromes (MDS)Clonal Cytopenia of Undetermined Significance (CCUS)1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Heart Failure: PF-07328948 Study

We are testing a new oral medication for adults with heart failure to see if it improves heart function and symptoms compared to a placebo. The study also examines the safety of this treatment.

Heart Failure6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Cerebral Palsy: IncobotulinumtoxinA Treatment

We are studying the safety and effectiveness of IncobotulinumtoxinA for children with upper and lower limb spasticity due to cerebral palsy. This trial includes both new and previously treated patients to see how well the treatment works.

Muscle Spasticity1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyPediatrics

Procizumab for Critical Cardiovascular Care

We are evaluating a new treatment for patients receiving critical care for cardiovascular issues. This study aims to understand its safety and potential benefits in this high-risk group.

Cardiogenic Shock>2 yearsSafety phase (I)CardiologyInternal Medicine

Blood Cancers: Trichostatin A Dose Study

We are exploring the highest safe dose of Trichostatin A for individuals with relapsed or refractory blood cancers. This study aims to ensure the treatment can be tolerated by patients.

Relapsed/Refractory Blood CancersSafety phase (I)HematologyOncology

CBD for Alcohol Use Disorder: A Phase II Trial

We are studying whether adding cannabidiol to standard treatment helps patients with severe alcohol use disorder stay abstinent after inpatient care. The trial also looks at the safety of CBD and its effects on withdrawal and anxiety symptoms.

Alcohol Use Disorder≤3 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesInternal MedicinePsychiatry

Chronic Kidney Disease: Vicadrostat and Empagliflozin Study

We are investigating whether starting vicadrostat with empagliflozin helps people with chronic kidney disease. The study compares two different ways of starting the medications to see which is more effective.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteDiabetologyNephrology

Drug Interaction Study: Itraconazole and AZD5004

We are investigating how multiple doses of itraconazole affect the movement of AZD5004 in healthy adults. Additionally, we’re looking at how AZD5004 influences the movement of hormones in healthy women.

Healthy Participants6-12 monthsSafety phase (I)Gynecology and ObstetricsInternal Medicine

Type 2 Diabetes: Retatrutide Study

We are evaluating how Retatrutide affects insulin secretion and sensitivity in adults with type 2 diabetes. This research may help improve diabetes management.

Diabetes Mellitus1-2 yearsSafety phase (I)EndocrinologyInternal Medicine

Type 2 Diabetes: Once-Weekly Retatrutide

We are investigating how well once-weekly Retatrutide works for people with type 2 diabetes and its effects on blood sugar levels. This study aims to understand the risk of hypoglycemia in participants.

Type 2 Diabetes6-12 monthsSafety phase (I)DiabetologyEndocrinology

Skin Inflammation and Antibiotic Effectiveness Study

We are examining how medications cause skin inflammation and how this affects antibiotic concentration in inflamed and healthy tissues. This research may help improve treatment strategies for skin infections.

Skin Inflammation>2 yearsSafety phase (I)DermatologyInfectious Diseases

Neovascular Age-Related Macular Degeneration: AI-Assisted Treatment

We are exploring how artificial intelligence can help improve treatment for patients with active neovascular AMD. This study aims to make the treatment process easier for patients and healthcare providers.

Neovascular Age-Related Macular Degeneration1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOphthalmology